1 Unveiling the threat: Characterization of *Clostridioides difficile* Infection in the

Northwest Region of Buenos Aires between 2019-2023 and Associated Risk
 Factors redefined through a Meta-Analysis

Angela María Barbero^{1,2,#}, Nicolás Diego Moriconi^{1,#}, Sabina Palma^{1,2,#}, Josefina
Celano¹, María Gracia Balbi³, Lorenzo Sebastián Morro¹, María Martina Calvo
Zarlenga⁴, Jorgelina Suárez^{3,5}, María Guadalupe Martínez³, Mónica Graciela
Machain³, Carlos Gabriel Altamiranda⁴, Gabriel Erbiti^{4,5}, Rodrigo Emanuel
Hernández Del Pino^{1,2, ζ}, Virginia Pasquinelli^{1,2, *, ζ}.

9 1 Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del
10 Noroeste de la Provincia de Buenos Aires (UNNOBA). B6000DNE, Buenos Aires,
11 Argentina.

2 Centro de Investigaciones y Transferencias del Noroeste de la Provincia de
 Buenos Aires (CIT NOBA), UNNOBA-Universidad Nacional de San Antonio de
 Areco (UNSAdA)-Consejo Nacional de Investigaciones Científicas y Técnicas
 (CONICET). Buenos Aires, Argentina.

16 3 Servicio de Laboratorio, Sala de Microbiología, Hospital Interzonal General de 17 Agudos (HIGA) Dr. Abraham F. Piñeyro, Junín, Buenos Aires, Argentina

18 4 Clínica Centro Médico Privado SRL, Junín, Buenos Aires, Argentina

5 Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA).
B6000DNE, Buenos Aires, Argentina.

- [#] Angela María Barbero, Nicolás Diego Moriconi and Sabina Palma share first
 authorship.
- ^ζ Rodrigo Emanuel Hernández Del Pino Rodrigo and Virginia Pasquinelli share the
 last authorship.
- *Corresponding author: virpasquinelli@gmail.com, Tel: +5492364582417, Address:
 Coronel Borges 379, Junín (Postal Code 6000), Buenos Aires, Argentina.

27 **Conflict of interest.** The authors declare that the research was conducted in the 28 absence of any commercial or financial relationships that could be construed as a 29 potential conflict of interest.

1 in 5 diarrheas is caused by *C. difficile* in the Northwest region of Buenos Aires,

31 Argentina. More than the 65% of the cases were community-acquired and involved

32 toxigenic strains. Comparison through meta-analysis identified known and also new

risk factors.

34 Abstract

Clostridioides difficile stands as the leading cause of hospital acquired enteric 35 infection in developed countries. In Argentina, the epidemiology of Clostridioides 36 difficile infection (CDI) is currently poorly characterized. Therefore, we conducted a 37 retrospective case-control study evaluating the prevalence of CDI in 249 stool 38 samples collected between 2019 and 2023 in the Northwest region of Buenos Aires. 39 The presence of *C. difficile* was detected by combining three techniques (EIA, PCR) 40 and toxigenic culture) in a diagnostic algorithm. Clinical and demographic data from 41 patients was also analyzed to identify CDI-associated risk factors. 1 in 5 patients 42 43 presented C. difficile as the etiological agent of diarrhea and the 80% of CDI+ cases carried toxigenic strains, most of which had been acquired in the community. Age 44 ≥69 years, previous use of antibiotics, previous hospitalization and previous 45 episodes of CDI emerged as predisposing factors for CDI in our study cohort. Blood 46 parameters such as an elevated number of leukocytes and platelets, a decreased 47 basophil count, and an increased urea concentration were identified as indicators of 48 49 CDI. We also carried out a systematic review and a meta-analysis where we contrasted our results with 39 studies selected from different countries around the 50 world. At the global level, the meta-analysis highlighted advanced age, previous 51 52 consumption of antibiotics and previous hospitalization as CDI risk factors and the leukocyte count as an indicator of CDI. These results emphasize the importance of 53 54 epidemiological studies and reveal crucial information for healthcare decisionmaking regarding CDI. 55

- 56 Keywords: C. difficile, epidemiology, risk factors, meta-analysis
- 57 Running title: Risk factors and meta-analysis of CDI



59 Introduction

Clostridioides difficile infection (CDI) is considered as the most frequent hospital-60 acquired disease ^{1,2}. Since 2019, the Centers for Disease Control (CDC) have 61 identified C. difficile as an "urgent threat", with the immediate need to implement 62 prevention and control actions ³. C. difficile is a Gram positive, anaerobic and spore-63 forming bacterium that causes intestinal damage primarily through the production of 64 two main toxins: toxin A (TcdA) and toxin B (TcdB)⁴. These toxins play a crucial role 65 in the pathogenesis of CDI by damaging the cells lining the gut. CDI can be life-66 threatening, ranging from mild diarrhea to pseudomembranous colitis and causing 67 68 nearly 500,000 cases per year in the United States ⁵.

CDI is also a major economic burden to the health care systems, which is closely 69 linked to the high recurrence rates of this infection. Although standard treatments 70 71 resolve CDI in most cases, up to 35% of CDI-treated patients will experiment a recurrence of the disease with aggravated symptoms ⁵. Common therapy for CDI 72 includes antibiotics such as metronidazole for mild cases and vancomycin or 73 74 fidaxomicin for moderate to severe cases ⁶. Therapies with the human antibody 75 bezlotoxumab against C. difficile toxin B or Fecal Microbiota Transplant (FMT) to restore the balance of the microbiome have been recommended to treat or prevent 76 77 recurrences ^{7,8}.

Regarding global epidemiology, while healthcare-associated CDI has declined in recent years, the incidence of community-acquired CDI is on the rise ^{9–14}. The main transmission route for *C. difficile* is through direct Person-to-Person contact by the fecal-oral route ¹⁵. *C. difficile* spores constitute the main form of resistance and can persist in the environment for long periods ^{16,17}. Then, contaminated surfaces, food or water, as well as asymptomatic carriers, are typical sources of community transmission ^{18–20}.

Several risk factors are associated with the development of CDI. The use of 85 antimicrobials with emphasis on broad-spectrum antibiotics, has been described as 86 the most significant risk factor for CDI ^{21,22}. These antibiotics can disrupt the normal 87 balance of bacteria in the gastrointestinal tract, generating dysbiosis and so allowing 88 C. difficile overgrow in the gut. Hospitalization in healthcare facilities and advanced 89 90 age, which can be related to weakened immune systems and a higher likelihood of residing in healthcare settings, also constitute important risk factors ²². The use of 91 stomach acid regulators, such as proton pump inhibitors (PPIs) and H2 blockers, 92 has been associated with an increased risk of CDI ²³; however, this is still under 93 debate. Previous episodes of CDI increase the risk of recurrence ²⁴. Finally, several 94 underlying health conditions that could compromise the immune system could 95 96 contribute to increased susceptibility or severity of the infection. Comorbidities such as Inflammatory Bowel Disease (IBD) ²⁵, Crohn's disease ²⁵, ulcerative colitis ²⁵, 97 diabetes ²⁶ and chronic kidney disease (CKD) ²⁷ can enhance the risk of CDI. 98

99 Certain clinical procedures (e.g. chemotherapy treatments and gastrointestinal 100 surgery), malnutrition or enteral nutrition, organ transplantation along with 101 immunosuppressive medications and blood disorders may also elevate the risk of 102 CDI ^{28,29}.

Understanding geographical variations in prevalence by studying CDI epidemiology 103 and risk factors is essential for preventing, controlling, and managing the infection. 104 In Latin America, and particularly in Argentina, comprehensive epidemiological data 105 on CDI are limited. It has been reported that patients with diarrhea are not routinely 106 tested for C. difficile in developing countries and, when tested, very often only the 107 enzyme immunoassay (EIA) is used ^{30–32}. This could lead to an underestimation in 108 the diagnosis and high economic burdens for the health system. Our retrospective 109 study (2019-2023) assesses the prevalence of C. difficile among health care centers 110 of the Northwest region of Buenos Aires, Argentina. Furthermore, with the aim to 111 characterize our study cohort, we analyzed the demographic and clinical data of the 112 patients and we conducted a meta-analysis to compare our findings with global 113 reports. 114

115 Methodology

116 Human Samples and Participating Institutions

The research was carried out in accordance with the Declaration of Helsinki (2013)
and approved by the UNNOBA (Universidad Nacional del Noroeste de la Provincia
de Buenos Aires) Ethics Committee (COENOBA).

Fecal samples from hospitalized adult patients with diarrhea were collected after obtaining informed consents and frozen at -20 °C until use. The samples were derived from the following health-care centers: Hospital Interzonal General de Agudos (HIGA) Abraham Félix Piñeyro, Clínica Centro Médico Privada SRL and Clínica IMEC. Samples received between January 1, 2019 and December 31, 2023 from Sanitary Region III of Buenos Aires, Argentina **(Supplementary Fig. 1)** were included in this analysis.

127 Patients characterization

The presence of *C. difficile* was determined in the fecal samples using a diagnostic algorithm **(Supplementary Fig. 2)** as recommended by Crobach et al. in 2016 ³³. Briefly, three tests were used in a retrospective approach: Enzyme immunoassay (EIA, CoproStripTM *C. difficile* GDH + Toxin A + Toxin B (Savyon® Diagnostics Ltd)), Polymerase Chain Reaction from stool samples (PCR, Taq Phire Tissue Direct PCR Master Mix (Thermo Fisher)) and Toxigenic culture (stool culture in CHROMAgarTM *C. difficile* plates + PCR from isolated *C difficile* colonies).

Patients were defined as CDI+ or CDI- and clinical, demographic and blood parameters were evaluated **(Table 1)**.

137 CDI classifications by setting of acquisition and severity were defined according to 138 the Infectious Diseases Society of America (IDSA) criteria ³⁴.

Clinical-demographical parameters	Blood parameters
Age	Leukocytes (cells/mm ³)
Biological Sex	Neutrophils (cells/mm ³)
Previous hospitalization	Monocytes (cells/mm ³)
Previous consumption of Antibiotics	Lymphocytes (cells/mm ³)
Antibiotics use during hospitalization	Eosinophils (cells/mm ³)
Presence of comorbidities	Basophils (cells/mm ³)

Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm ³)
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

139

Table 1. Clinical, demographic and blood parameters evaluated in CDI+ and CDI-patients.

142 Meta-analysis design

A bibliographic search was carried out using PubMed and Google Scholar databases
 in addition to the AI SciSpace tool. The reports that fulfilled the definition criteria of
 cases and controls were selected. The meta-analysis workflow is summarized in Fig.
 4.

147 Statistical Analysis

For clinical, demographic and blood parameters comparisons, parametric t-test or
 non-parametric Mann-Whitney test for unpaired samples were used. Fisher's exact
 test was used to analyze the frequency distribution of qualitative/nominal variables.
 Data was analyzed using GraphPad Prism 8.0.1 software (San Diego, CA, USA) and
 p values <0.05 were considered statistically significant.

For the meta-analysis, the "Metafor" package from RStudio (2023.06.1+524 version) was used ³⁵. The Odds Ratio (OR, for categorical variables) and the Standardized Mean Difference (SMD, for continuous variables) were calculated and a REML (Random Effect Maximum Likelihood) model was employed. Models with a p value <0.05 were considered as potential predictors of CDI incidence risk.

158 **Results and Discussion**

159 **CDI prevalence in Northwest Buenos Aires**

In Argentina, studies and reports on CDI are scarce and heterogeneous ^{36–39}. In order to contribute to a better understanding of the disease, we conducted a retrospective analysis of 249 fecal samples received between 2019-2023 from Sanitary Region III of Buenos Aires.

We determined *C. difficile* as the causal agent of one in five diarrheas (21.29%) **(Fig. 1 a)** and we detected that more than the 80% of the patients were infected with toxigenic strains; indicated by the presence of *C. difficile* Toxin B in the stool samples **(Fig. 1 b)**. This percentage was similar to the worldwide reported prevalence, where CDI is the underlying cause of 15 to 20% of diarrhea associated with the use of antibiotics ⁴⁰.

170 When analyzing the cases on an annual basis, the frequency of CDI ranged around 20% from 2019 to 2023 (Fig. 1 c). Interestingly, the highest incidence in our study 171 172 cohort was observed during 2020, duplicating the percentage of CDI+ cases 173 compared to the rest of the years (Fig. 1 c). In relation to this, the COVID-19 pandemic brought about the preventive use of broad-spectrum antibiotics to avoid 174 bacterial coinfections; which could be associated with the increase in detection ⁴¹⁻⁴⁴. 175 Nevertheless, CDI detection could have been impacted by the decrease in the 176 number of tests, a fact that was corroborated in multiple studies carried out during 177 the early stages of the pandemic ^{45–47}. Additionally, there could also be an 178 underestimation of CDI cases ^{48,49} since SARS-CoV-2 frequently causes 179 gastrointestinal symptoms similar to those of C. difficile ⁵⁰. 180

Regarding the severity of the diarrhea, all infected patients had a moderate 181 classification (Fig. 1 d). Importantly, the majority of CDI infections occurred in the 182 community setting (Fig. 1 e). 65.71% of the patients presented community-acquired 183 184 CDI, 14.29% in geriatric institutions and only the remaining 20% occurred in a hospital environment (Fig. 1 e). This is particularly notable, since the epidemiology 185 of CDI has changed in the last two decades. The 027 strain, responsible for clinical 186 outbreaks in the early 2000s ⁵¹, has recently decreased its incidence in part due 187 fluoroquinolones restriction, prevention measures and to improvements in detection 188 tests that have allowed a better characterization of the circulating ribotypes ^{52–56}. 189 Additionally, an increase in strains associated with community infection (e.g. 078, 190 191 014 in Europe and 106 in the US) has been reported in recent years, with communityacquired cases rising above 40% ^{11,57–59}. 192

193

194



196

197 **Figure 1.** CDI prevalence in Northwestern Buenos Aires.

249 stool samples were evaluated using the diagnostic algorithm. a) Donut graph
showing positive, negative and discordant results for the presence of *C. difficile*. b)
Donut graph showing the percentage of toxigenic strains (presence of Toxin B)
detected in the stool samples. c) CDI+ and CDI- results classified on an annual basis
from 2019 to 2023. d) CDI classification. e) Origin of the CDI+ patients at the time of
diagnosis.

204

205 Risk factors

After classifying the patients as CDI+ or CDI-, we determined the risk factors that could be involved in the prevalence of CDI.

As seen in **Fig. 2 a**, we found significant differences in the age of CDI+ and CDIpopulations, with the CDI+ patients presenting a higher average age (CDI+: mean = 72 years vs. CDI-: mean = 65 years). By using a ROC curve analysis, we established a cut-off point of 69 years for advanced age as a risk factor in our cohort (**Fig. 2 b**). Elderly patients have a greater probability of receiving broad-spectrum antibiotics, being hospitalized or staying longer in hospital settings partly due to the presence of comorbidities ^{60,61}.

With age, the immune system decreases its functions and also older individuals develop inflammageing, which could impact in the resolution of the infection; a fact

that was observed for neutrophils 62 and serum IgG against *C. difficile* toxins $^{63-65}$.

Regarding biological sex, no differences were found for the proportion of males and females between both patient populations **(Fig. 2 c)**.

220 Consumption of antibiotics in the 3 months prior to the diagnosis of CDI, as well as previous hospitalizations and infections with C. difficile, could be considered risk 221 factors that predisposes to CDI in our study cohort (Fig. 2 d, e and f). Hospitals and 222 healthcare facilities are common environments for C. difficile transmission since they 223 can be easily colonized by spores that persist on surfaces for months ^{66,67}. Previous 224 consumption of antibiotics is directly related to the dysbiosis of the microbiota that 225 226 enables the colonization of C. difficile and is typically consider as the main risk factor for CDI ^{68,69}. Some antibiotics, such as clindamycin, broad-spectrum penicillins, 227 cephalosporins and fluoroquinolones alter the microbiota to a greater extent than 228 others ^{68,70,71}. When analyzing the families of antibiotics consumed by CDI+ patients, 229 we observed that 56.52% had taken some kind of penicillin prior to diagnosis (Fig. 230 2 g). 231

On the other hand, the consumption of proton pump inhibitors (PPI) prior to diagnosis and the presence of comorbidities did not show significant differences between CDIand CDI+ patients (**Fig. 2 h and i**). **Fig. 2 j** shows a breakdown of the comorbidities reported in the patients under study. Although they were analyzed individually, no substantial variations were found between the CDI+ and CDI- population for any of them.

No differences were found regarding the variables referring to the evolution of patients during admission to health centers such as *hospitalization in common floor* or *ICU*, need for *ICU*, shock and death **(Supplementary Fig. 3)**.

241

242



245 Figure 2. CDI associated risk factors.

Evaluation of risk factors associated with CDI. a) Age (years), b) ROC curve to establish the age cut-off point, c) biological sex, d) prior antibiotics (ATB) consumption, e) prior hospitalization, f) prior CDI, g) antibiotic breakdown by family, h) prior PPI consumption, i) comorbidities, j) breakdown of specific comorbidities (the white number inside the bars represents the number of patients with the comorbidity).

a) Mann-Whitney test. c, d, e, f, h, and i) Fisher's exact test. Stacked bars represent
 the percentage of patients for each parameter. ns= non-significant; *, p

254 Blood and serum parameters

We also analyzed the patients' blood counts and serum parameters that were measured on the day of fecal sample collection.

257 We observed a significant increase in the number of leukocytes (Fig. 3 a) and 258 platelets (Fig. 3 j) in patients infected with C. difficile. When analyzing the count of lymphocytes, monocytes and neutrophils individually between both patient 259 260 populations, although an increase was evident, we did not find significant differences 261 (Fig. 3 b, c and d). However, it is important to note that CDI+ patients had increased at least two of these leukocyte populations compared to CDI- patients at the time of 262 diagnosis (Fig. 3 e, f and g). Although some studies have highlighted that an 263 elevated white blood cell (WBC) count is frequently observed in the context of CDI 264 ⁷² ⁷³ ⁷⁴, little has been explored in using elevated WBC count as a predictor of this 265 infection. In this regard, we agree with Vargas et al. ⁷⁵ in that the total leukocyte 266 count alone is not a specific indicator for CDI. Previous work evaluating platelet count 267 in CDI episodes reported controversial results, assigning them both a beneficial and 268 detrimental role in relation to clinical symptoms ^{76–85}. We have recently shown that 269 platelets bind to C. difficile and promote its uptake by human macrophages using 270 macropinocytic pathways ⁸⁶. Therefore, we consider that platelets in CDI could be 271 fundamental for the resolution of the infection and that further studies are needed to 272 unravel their role during CDI. 273

Regarding the rest of the blood parameters evaluated, while a significant decrease
in basophils count was observed (Fig. 3 h), the eosinophil count was not affected by
the presence of *C. difficile* (Fig. 3 i). To the best of our knowledge, to date there are
no reports on the role of basophils in CDI. Nevertheless, the potential role of CCL-5,
a basophilic recruiter chemokine, has been highlighted in CDI ^{87,88}

No differences were evident for creatinine and albumin levels (Fig. 3 j and k), but
an elevated urea concentration stood out in patients infected with *C. difficile* (Fig. 3
m). Moreover, the BUN (Blood Urea Nitrogen)/Creatinine ratio was significantly
elevated in CDI patients (Fig. 3 n). Elevated BUN ratios have been associated with
complications of CDI ⁸⁹ as well as with higher mortality rates ⁹⁰ and high urea levels
were also proposed as a risk factor for severe CDI ⁹¹.



Figure 3. Blood and serum parameters in CDI+ and CDI- patients.

Number of a) Leukocytes (cells/mm³), b) lymphocytes (cells/mm³), c) monocytes (cells/mm³), d) neutrophils (cells/mm³), e) lymphocytes plus monocytes (cells/mm³), f) lymphocytes plus neutrophils (cells/mm³), g) neutrophils plus monocytes (cells/mm³), h) basophils (cells/mm³), i) eosinophils (cells/mm³) and j) platelets (cells/mm³). Levels of k) creatinine (mg/dl), l) albumin (g/dl) and m) urea (mg/dl). n)

BUN (blood urea nitrogen)/creatinine ratio.

a-i and k-n) Mann-Whitney test. j) unpaired t test. Violin plots show the distribution
of the data. ns= non-significant; *, p<0.05; **, p<0.01.

295 Meta-analysis

296 We finally performed a meta-analysis to obtain more robust and reliable conclusions

about the CDI associated parameters evaluated in our cohort. We defined the selection criteria (**Fig. 4 a**) and carried out a systematic review that allowed us to

select 40 independent case/control type studies (**Table 2**) from the countries shown

in light grey in **Fig. 4 b**.

301



302

303

304

305

306

308

309

Figure 4. Flow chart of the studies and countries screened and included in the Metaanalysis.

a) The obtained results regarding clinical and demographic characteristics of the
CDI+ and CDI- patients in our cohort were contrasted against findings of other
studies through a meta-analysis by RStudio package "Metafor". After initial
identification, eligibility criteria were applied and 39 reports were included in the
meta-analysis along with our data. CDI- patients were considered as the control
group.

b) World map showing the countries from which the studies included in the metaanalysis come (light gray). The circles contain the number of studies selected per
country.

- 321
- 322
- 323
- 324
- 325

Countries	Studies		
Argentina	Lopardo, G. et al, 2015 ³⁹		
Aigentina	OUR study		
Brazil	Lopes Cançado, G. G. et al, 2018 ⁹²		
Canada	Lowe, D. O. et al, 2006 93		
	Dai, W. et al, 2020 94		
	Li, Y. et al, 2016		
China	Lv, Z. et al, 2014 96		
	Tang, C. et al, 2018 97		
	Zhou, F, F, et al, 2014 ⁹⁶		
Colombia	Carvajal, C. et al, 2017 ³⁹		
D	Salazar, C, L. et al, 2017 ¹⁰⁰		
Denmark	Soes, L. M. et al, 2014 ¹⁰¹		
France			
Hungary	Kurti, Z. et al, 2015 ¹⁰⁰		
Icelano			
India	Ingle, M. et al. 2013 $\frac{106}{100}$		
lanan	Mori N et al 2015		
Mexico	Morfin-Otero R et al 2016 108		
Poland			
	Legenza, L. et al. 2018 ¹¹⁰		
South Africa	Rajabally, N. et al. 2013 ¹¹¹		
South Korea	Han, S. H. et al, 2014 ¹¹²		
Taiwan	Lee, Y. C. et al, 2012 ¹¹³ ; Lin		
Taiwan	C. Y. et al, 2022 ¹¹⁴		
Thailand	Thipmontree, W. et al, 2011 ¹¹⁵		
Turkey	Ergen, E. K. et al, 2009 ¹¹⁶		
	Dial, S. et al, 2005 ¹¹⁷		
	Dial, S. et al, 2008 ¹¹⁸		
United Kingdom	Marwick, C. A. et al, 2013 ¹¹⁹		
	Suissa, D. et al, 2012 ¹²⁰		
	Wilcox, M. H. et al, 2008 ¹²¹		
	Baxter, R. et al, 2008 ¹²²		
	Haddad, F. G. et al, 2019 ¹²³		
	Kutty D K at al 2010 127		
United States	Kwop S at al 2017 126		
	Naggie S et al 2017 127		
	Tabak P V et al 2015 ¹²⁸		
	Tartof S Y et al 2015 ¹²⁹		

326

327

Table 2. Countries and studies included in the meta-analysis.

331	RISK PREDICTOR	OR
	Age	1,19 **
332	Biological sex	0,89 *
	Prior ATB consumption	3,02 ***
333	Prior PPI consumption	1,29 ns
	Prior hospitalization	2,45 ***
334	Prior CDI	1,76 ns
	WBC (10 ⁹ cel/mm ³)	1,35 *
335	Platelets (10 ⁹ cel/ mm ³)	1,54 ns
	Comorbidities	
336	Diabetes <i>mellitus</i>	1,26 ns
	Heart disease	1,41 *
337	Kidney disease	2,23 ***
	HIV	1,00 ns
338		

The effects for each of the variables evaluated in the meta-analysis are summarized in **Table 3**.

Table 3. Summary of risk predictors from the meta-analysis.

The dataset included 11,596 individuals with CDI and 536,467 matched controls (**Table 4**). Overall, the distribution of biological sex was 40.06% male vs. 59.94% female, being 44.33% vs. 55.67% in the CDI+ population and 39.98% vs. 60.02% in the control group. The demographic parameters Age (OR= 1.19; 95% CI, 1.06 to 1.35) and Biological Sex (OR= 0.89; 95% CI, 0.81 to 0.99) obtained significant models, which implies that, globally, advanced age and female biological sex are associated with a higher risk of CDI (**Fig. 5 a and b**).

347 9.11% of the included individuals were previously exposed to antibiotics and 22.18% to PPI. Both antibiotic (CDI+ 39.95% vs. CDI- 8.52%) and PPI (CDI+ 29.87% vs. 348 CDI- 21.76%) consumption was higher among those patients infected with C. difficile 349 (Table 4). In this analysis, which ignored antibiotic subclasses, we found that the 350 351 pooled impact of any antibiotic exposure (OR= 3.02; 95% CI, 2.32 to 3.94) increased the risk of CDI by a multiple of 3 (Fig. 5 c). A longer duration of antibiotic therapy, 352 as well as a greater number of antibiotics administered increase the probability of 353 354 CDI ⁷⁰. The risk of acquiring CDI could be 8 to 10 times higher during antibiotic 355 therapy, even three months after its completion, with the first month being the one with the highest risk ¹³⁰. 356

Regarding PPIs as risk factors for CDI, there is an arduous discussion with some reports showing around 40-71.4% of hospitalized patients received PPI therapy during hospitalization ^{131–133} and others supporting the idea that PPIs could trigger long-term adverse effects trough changes on the microbiota composition ^{134,135}. In our meta-analysis, there was no evidence of the impact of PPI on CDI risk (**Fig. 5 d**). Previous hospitalization emerged as the second most influential predictor for CDI risk (OR= 2.46; 95% CI, 1.90 to 3.17) (**Fig. 5 e**). Among the CDI+ patients included in the meta-analyses, 27.88% had been hospitalized prior to diagnosis (**Table 4**) while only 16.80% in the control group.

Previous episodes of CDI are widely reported as a risk factor for subsequent cases and/or recurrences in patients. However, in this meta-analysis previous CDI was not a predictor of risk (**Fig. 5 f**) which could be attributed to the fact that only 4 of the 40 included studies provided this type of data ^{56,103,120,123}. Actually, when evaluating the Forest Plot for this variable in detail, the studies show the same trend as our epidemiological study when considering previous CDI as a risk factor.

When evaluating comorbidities, both heart diseases (OR= 1.41; 95% CI, 1.02 to 373 374 1.94) and chronic kidney disease (OR= 2.23; 95% CI, 1.38 to 3.61) exhibited models with significant effects (Fig. 5 g and h), indicating that these pathologies increase 375 the risk of CDI. The rest of the tested comorbidities were not associated with a higher 376 risk of infection (Fig. 5 i and j). The presence of comorbidities has been widely 377 reported as a condition that facilitates colonization and infection by C. difficile ¹³⁶. A 378 previous meta-analysis found IBD, diabetes, leukemia or lymphoma, kidney failure 379 and solid cancer as the CDI risk-related comorbidities ¹³⁷. 380

Finally, blood parameters were analyzed. Increased leukocytes count was also a potential predictor of CDI according to our comparative analysis (OR= 1.36; 95% CI, 1.05 to 1.75) (**Fig. 5 k**). Although the number of platelets did not show a statistically significant effect (**Fig. 5 I**), it is important to note that only 2 studies apart from ours evaluated this parameter.

386

387			CDI+	CDI-	TOTAL
200	N° of individuals		11596	536467	548467
388		Male	44.33%	39.98%	40.06%
389	Sex	Female	55.67%	60.02%	59.94%
	Drior ATR concumption	With	39.95%	8.52%	9.11%
390	Prior ATE consumption	Without	60.05%	91.48%	90.89%
391	Prior PPI consumption	With	29.87%	21.76%	22.18%
	Prior PPI consumption	Without	70.13%	78.24%	77.82%
392	Brier beenitelization	With	27.88%	16.80%	17.07%
393		Without	72.12%	83.20%	82.93%

394 **Table 4.** Meta-analysis dataset.

Figure 5 Forest plots of risk predictors.

Forest plots representative of each variable evaluated in the meta-analysis. a) Age, b) biological sex, c) previous ATB consumption, d) previous PPI consumption, e) prior hospitalization, f) prior CDI, g) heart disease, h) chronic kidney disease, i) diabetes *mellitus*, j) HIV, k) white blood cells (WBC) count (cells/mm³), l) platelets count (cells/mm³).

403 A REML (Random Effect Maximum Likelihood, gray diamond) random effects model 404 was applied. Models with p<0.05 (OR/SMD ± CI values less or greater than 1) were 405 considered as potential risk predictors for CDI. Black diamonds represent the means 406 of each of the variables in each study. Bars indicate the lower and upper confidence 407 extremes. Our study (white diamond) is mentioned as *OUR STUDY*.

408 OR= odds ratio. SMD= standard media deviation. CI= confidence interval

410 **Conclusions**

We have defined risk factors associated with CDI and detected modulations in different blood parameters in our study cohort in Argentina. We have also explored the relevance of our findings at a global level by a systematic review and metaanalysis. Our results emphasize the need to detect *C. difficile* as a causal agent of infectious diarrhea in a country where testing is not standardized or routinely performed in the health institutions. Our report provides valuable insights that could contribute to a more efficient surveillance of CDI, diagnosis and follow-up of patients.

418 Author contributions

- 419 Conceptualization: all authors
- 420 Formal analysis: AMB, NDM, JC, SP, LSM and REHDP.
- 421 Funding acquisition: AMB, SP, REHDP and VP.
- 422 Investigation: AMB, NDM, SP, REHDP and VP.
- 423 Methodology: all authors.
- 424 Software: NDM and REHDP.
- 425 Supervision: REHDP and VP.
- 426 Writing: AMB wrote the original draft. All authors contributed to the review & editing 427 of this manuscript.

428 Role of the funding source

This work was supported by Universidad Nacional del Noroeste de la Provincia de 429 Buenos Aires [grant numbers SIB 0618/2019, SIB 2113/2022 and "Proyectos de 430 431 Investigación Interdisciplinarios de la UNNOBA" Res. CS 2190/2022, to VP]. Agencia Nacional de Promoción Científica y Tecnológica, Fondo para la 432 Investigación Científica y Tecnológica [ANPCyT-FONCyT, grant numbers PICT A 433 2017-1896 and PICT-2021-I-A-01119 to VP: PICT 2018-03084 IB to RHDP, PICT-434 2021-I-INVI-00584 to AB and PICT-2021-I-INVI-00208 to SP]. UNNOBA FONCyT 435 [grant number PICTO 2019-00007 to RHDP and VP]. Consejo Nacional de 436 Investigaciones Científicas y Técnicas [CONICET, grant number PIP 2021 437 11220200103137CO to VP and RHDP]. 438

439 Acknowledgements

We thank all the patients who voluntarily participated of this study. We also thank
Natalia Menite, Lucia Romano and Gastón Villafañe for their technical assistance.
We acknowledge the laboratory personnel, medical staff and biochemists who have
collaborated in the collection of samples and data during the study period of this
report. Finally, we thank Flaticon for the icons used in the graphical abstract of this
work.

446 **References**

- 447 1. Brazier JS. . 1998;47–57.
- 448 2. Zhang S, Palazuelos-Munoz S, Balsells EM, et al. . *BMC Infect Dis*;16 . Epub 449 ahead of print 2016. DOI: 10.1186/s12879-016-1786-6.
- 450 3. Center for Disease Control and Prevention. . *CDC*;10. Epub ahead of print
 451 2019. DOI: 10.1186/s13756-020-00872-w.
- 452 4. Smits WK, Lyras D, Lacy DB, et al. . DOI: 10.1038/nrdp.2016.20.
- 453 5. Feuerstadt P, Theriault N, Tillotson G. . BMC Infect Dis. 2023;23:1–8.
- 454 6. Di X, Bai N, Zhang X, et al. . *Brazilian J Infect Dis*. 2015;19:339–349.
- 455 7. Bainum TB, Reveles KR, Hall RG, et al. . *Microorganisms*. 2023;11:1–22.
- 456 8. Phanchana M, Harnvoravongchai P, Wongkuna S, et al. . World J
 457 Gastroenterol. 2021;27:7210–7232.
- 458 9. Burke KE, Lamont JT. . *Gut Liver*. 2014;8:1–6.
- 459 10. Freeman J, Bauer MP, Baines SD, et al. . *Clinical Microbiology Reviews*.
 460 2010;23:529–549.
- 461 11. Goorhuis A, Bakker D, Corver J, et al. . *Clin Infect Dis.* 2008;47:1162–1170.
- 462 12. Chitnis AS, Holzbauer SM, Belflower RM, et al. . *JAMA Intern Med*.
 463 2013;173:1359–1367.
- 464 13. Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, et al. . *Obstet Gynecol.*2018;131:387–391.
- 466 14. Gupta A, Khanna S. . *Infect Drug Resist.* 2014;7:63–72.
- 467 15. Alice Y. Guh, MD, MPH and Preeta K. Kutty, MD M. . *Physiol Behav*.
 468 2019;169:248–256.
- 469 16. Lawler AJ, Lambert PA, Worthington T. . *Trends Microbiol*. 2020;28:744–
 470 752.
- 17. Paredes-Sabja D, Shen A, Sorg JA. . *Trends Microbiol*. 2014;22:1–15.
- 472 18. Hernández Del Pino RE, Barbero AM, Español LÁ, et al. . *J Leukoc Biol*.
 473 2021;109:195–210.
- 474 19. Lim SC, Knight DR, Riley T V. . *Clin Microbiol Infect*. 2020;26:857–863.
- 475 20. Donskey CJ. . Clin Infect Dis. 2010;50:1458–1461.
- 476 21. Dicks LMT. . *Microorganisms*;11 . Epub ahead of print 2023. DOI:
 477 10.3390/microorganisms11092161.
- 478 22. Czepiel J, Dróżdż M, Pituch H, et al. . *Eur J Clin Microbiol Infect Dis Off*479 *Publ Eur Soc Clin Microbiol.* 2019;38:1211–1221.

- 480 23. Huang CH, Tseng YH, Tsai WS, et al. . *Infect Dis Ther* . Epub ahead of print 481 2024. DOI: 10.1007/s40121-024-00922-5.
- 482 24. Song JH, Kim YS. . *Gut Liver*. 2019;13:16–24.
- 483 25. Nitzan O, Elias M, Chazan B, et al. . *World J Gastroenterol*. 2013;19:7577– 484 7585.
- 485 26. Qu H-Q, Jiang Z-D. . *Diabetes Res Clin Pract*. 2014;105:285–294.
- 486 27. Dudzicz S, Wiecek A, Adamczak M. . *J Clin Med*. 2021;10:1–13.
- 487 28. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. . *World J Emerg Surg.*488 2015;10:1–23.
- 489 29. Khanna S, Pardi DS. . Mayo Clin Proc. 2012;87:1106–1117.
- 490 30. Curcio D, Cané A, Fernández FA, et al. . *Infect Dis Ther*. 2019;8:87–103.
- 491 31. Roldan GA, Cui AX, Pollock NR. . *J Clin Microbiol*;56 . Epub ahead of print
 492 March 2018. DOI: 10.1128/JCM.01747-17.
- 493 32. Acuña-Amador L, Quesada-Gómez C, Rodríguez C. . *Anaerobe*;74 . Epub 494 ahead of print 2022. DOI: 10.1016/j.anaerobe.2022.102547.
- 495 33. Crobach MJT, Planche T, Eckert C, et al. . *Clin Microbiol Infect*.
 496 2016;22:S63–S81.
- 497 34. Johnson S, Lavergne V, Skinner AM, et al. . *Clin Infect Dis*. 2021;73:e1029– 498 e1044.
- 499 35. Viechtbauer W. . J Stat Softw. 2010;36:1–48.
- 500 36. Fernandez Canigia L, Nazar J, Arce M, et al. . *Rev Argent Microbiol*.
 501 2001;33:101–107.
- 502 37. Legaria MC, Lumelsky G, Rosetti S. . Anaerobe. 2003;9:113–116.
- 38. Goorhuis A, Legaria MC, van den Berg RJ, et al. . *Clin Microbiol Infect.*2009;15:1080–1086.
- S05 39. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. . *Brazilian J Infect Dis*.
 2015;19:8–14.
- 50740.Bartlett JG, Gerding DN. . Clinical Infectious Diseases;46 . Epub ahead of508print January 2008. DOI: 10.1086/521863.
- 509 41. Pan L, Mu M, Yang P, et al. . *Am J Gastroenterol*. 2020;115:766–773.
- 510 42. Granata G, Petrosillo N, Al Moghazi S, et al. . *Anaerobe*. 2022;74:102484.
- Huttner BD, Catho G, Pano-Pardo JR, et al. . *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2020;26:808–810.
- 513 44. Chen N, Zhou M, Dong X, et al. . Lancet (London, England). 2020;395:507-

514	51	3
-----	----	---

- Adams-Sommer V, Fu Y, Grinspan LT, et al. . *Infect Control Hosp Epidemiol*.
 2021;42:1165–1166.
- 517 46. Laszkowska M, Kim J, Faye AS, et al. . *Dig Dis Sci*. 2021;66:4398–4405.
- 518 47. Hawes AM, Desai A, Patel PK. . Anaerobe. 2021;70:102384.
- 48. Luo M, Liu Y, Wu P, et al. . 8 . Epub ahead of print 2017. DOI:
 10.3389/fphys.2017.00822.
- 521 49. Khanna S, Kraft CS. . *Future Microbiol*. 2021;16:439–443.
- 522 50. Tariq R, Saha S, Furqan F, et al. . *Mayo Clin Proc*. 2020;95:1632–1648.
- 523 51. Louie TJ, Cannon K, Byrne B, et al. . *Clin Infect Dis an Off Publ Infect Dis* 524 *Soc Am.* 2012;55 Suppl 2:S132-42.
- 525 52. Guh AY, Mu Y, Winston LG, et al. . *N Engl J Med*. 2020;382:1320–1330.
- 526 53. Gentry CA, Williams RJ 2nd, Campbell D. . *Diagn Microbiol Infect Dis*. 527 2021;100:115308.
- 528 54. McDermott LA, Thorpe CM, Goldstein E, et al. . *Open Forum Infect Dis*. 2022;9:ofac492.1299.
- 530 55. Dingle KE, Didelot X, Quan TP, et al. . *Lancet Infect Dis.* 2017;17:411–421.
- 531 56. Wilcox MH, Shetty N, Fawley WN, et al. . *Clin Infect Dis.* 2012;55:1056– 532 1063.
- 533 57. Khanna S, Pardi DS, Aronson SL, et al. . Am Coll Gastroenterol;107.
- 534 58. European Centre for Disease Prevention and Control. . *Annu Epidemiol Rep* 535 *Commun Dis Eur*. 2016;40:335–348.
- 536 59. Carlson TJ, Blasingame D, Gonzales-Luna AJ, et al. . *Anaerobe*. 2020;62:102142.
- 538 60. Kincaid SE. Consult Pharm J Am Soc Consult Pharm. 2010;25:834–836.
- 539 61. Owens RC. . Drugs. 2007;67:487-502.
- 540 62. Bassaris HP, Lianou PE, Legakis NJ, et al. . *Med Microbiol Immunol*. 541 1984;173:49–55.
- 542 63. Nakamura S, Mikawa M, Nakashio S, et al. . *Microbiol Immunol*.
 543 1981;25:345–351.
- 544 64. Bacon AE, Fekety R. . *Diagn Microbiol Infect Dis*. 1994;18:205–209.
- 545 65. Simor AE, Bradley SF, Strausbaugh LJ, et al. . *Infect Control Hosp* 546 *Epidemiol*. 2002;23:696–703.
- 547 66. Guerrero DM, Nerandzic MM, Jury LA, et al. . Am J Infect Control.

Edwards AN, Karim ST, Pascual RA, et al. . Front Microbiol. 2016;7:1698.

Clark T, Wiselka M. . Clin Med. 2008;8:544-547.

Schroeder MS. . Am Fam Physician. 2005;71:921-928.

2012;40:556-558.

548

549

550

551

67.

68.

69.

552	70.	Hessen MT Ann Intern Med. 2010;153:ITC41-15; quiz ITC416.
553 554	71.	Dubberke ER, Wertheimer AI <i>Infect Control Hosp Epidemiol</i> . 2009;30:57–66.
555	72.	Wanahita A, Goldsmith EA, Marino BJ, et al Am J Med. 2003;115:543–546.
556 557	73.	Wanahita A, Goldsmith EA, Musher DM <i>Clin Infect Dis an Off Publ Infect Dis Soc Am</i> . 2002;34:1585–1592.
558 559	74.	Bulusu M, Narayan S, Shetler K, et al <i>Am J Gastroenterol</i> . 2000;95:3137–3141.
560	75.	Vargas E, Apewokin S, Madan R Anaerobe. 2017;45:101–105.
561	76.	Mihăilă RG, Cătană C, Olteanu AL, et al <i>Biomarkers</i> . 2019;24:389–393.
562 563	77.	Buchrits S, Gafter-Gvili A, Bishara J, et al <i>J Clin Med</i> ;10 . Epub ahead of print July 2021. DOI: 10.3390/jcm10132957.
564	78.	Lee DY, Chung EL, Guend H, et al Ann Surg. 2014;259:148–156.
565	79.	Byrn JC, Maun DC, Gingold DS, et al Med Hist. 2012;143:150–154.
566 567	80.	Nseir W, Khamisy-Farah R, Amara A, et al <i>Isr Med Assoc J</i> . 2019;21:658–661.
568	81.	Allegretti JR, Marcus J, Storm M, et al Dig Dis Sci. 2020;65:1761–1766.
569	82.	Zhao L, Luo Y, Bian Q, et al Infect Drug Resist. 2020;13:171–181.
570	83.	Pant C, Madonia PN, Jordan P, et al J Investig Med. 2009;57:40-42.
571	84.	Yan D, Chen Y, Lv T, et al <i>J Med Microbiol</i> . 2017;66:1483–1488.
572 573	85.	Phanchana M, Phetruen T, Harnvoravongchai P, et al Sci Rep. 2020;10:1–8.
574	86.	Barbero AM, Hernández Del Pino RE, Fuentes F, et al 2024;1–14.
575	87.	Rao K, Erb-Downward JR, Walk ST, et al PLoS One. 2014;9:e92578.
576	88.	Abhyankar MM, Ma JZ, Scully KW, et al Am Soc Microbiol. 2020;11:1–10.
577 578	89.	Abou Chakra CN, McGeer A, Labbe AC, et al <i>Clin Infect Dis</i> . 2015;61:1781–1788.
579 580	90.	Sartelli M, Di Bella S, McFarland L V., et al <i>World J Emerg Surg</i> . 2019;14:1–29.

- 581 91. Bermejo Boixareu C, Tutor-Ureta P, Ramos Martínez A. . *Rev Esp Geriatr* 582 *Gerontol.* 2020;55:225–235.
- 583 92. Lopes Cançado GG, Silveira Silva RO, Rupnik M, et al. *Anaerobe*. 2018;54:65–71.
- 585 93. Lowe DO, Mamdani MM, Kopp A, et al. Proton Pump Inhibitors and
 586 Hospitalization for Clostridium Difficile-Associated Disease: A Population587 Based Study.
- 588 94. Dai W, Yang T, Yan L, et al. . *BMC Infect Dis*;20 . Epub ahead of print April 2020. DOI: 10.1186/s12879-020-05014-6.
- 590 95. Li Y, Huang Y, Li Y, et al. . *Pakistan J Med Sci*. 2016;32:736–741.
- 591 96. Lv Z, Peng GL, Su JR. . *Brazilian J Med Biol Res*. 2014;47:1085–1090.
- 592 97. Tang C, Li Y, Liu C, et al. . *Am J Infect Control*. 2018;46:285–290.
- 593 98. Zhou FF, Wu S, Klena JD, et al. . *Eur J Clin Microbiol Infect Dis*.
 594 2014;33:1773–1779.
- 595 99. Carvajal C, Pacheco C, Jaimes F. . *Biomedica*. 2017;37:53–61.
- Salazar CL, Reyes C, Atehortua S, et al. . *PLoS One*;12 . Epub ahead of
 print September 2017. DOI: 10.1371/journal.pone.0184689.
- 598 101. Soes LM, Holt HM, Böttiger B, et al. . *Epidemiol Infect*. 2014;142:1437–1448.
- 599 102. Le Monnier A, Candela T, Mizrahi A, et al. J Hosp Infect. 2022;129:65–74.
- 600 103. Kurti Z, Lovasz BD, Mandel MD, et al. . World J Gastroenterol.
 601 2015;21:6728–6735.
- 104. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, et al. . *Eur J Clin Microbiol Infect Dis.* 2012;31:2601–2610.
- 105. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2011;30:89–
 93.
- 106. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2013;32:179–
 183.
- 608 107. Mori N, Aoki Y. . J Infect Chemother. 2015;21:864–867.
- Morfin-Otero R, Garza-Gonzalez E, Aguirre-Diaz SA, et al. . *Brazilian J Infect Dis*. 2016;20:8–13.
- 109. Czepiel J, Biesiada G, Brzozowski T, et al. J Physiol Pharmacol an Off J
 Polish Physiol Soc. 2014;65:695–703.
- Legenza L, Barnett S, Rose W, et al. . *BMJ Glob Heal*;3 . Epub ahead of
 print July 2018. DOI: 10.1136/bmjgh-2018-000889.
- 111. Rajabally N, Pentecost M, Pretorius G, et al. . South African Med J.

- 616 2013;103:168–172.
- 617 112. Han SH, Kim H, Lee K, et al. J Med Microbiol. 2014;63:1542–1551.
- 618 113. Lee YC, Wang JT, Chen AC, et al. J *Microbiol Immunol Infect*.
 619 2012;45:287–295.
- Lin C-Y, Cheng H-T, Kuo C-J, et al. . *Microbiol Spectr*,10. Epub ahead of
 print August 2022. DOI: 10.1128/spectrum.00486-22.
- Thipmontree W, Kiratisin P, Manatsathit S, et al. Epidemiology of Suspected
 Clostridium difficile-Associated Hospital-Acquired Diarrhea in Hospitalized
 Patients at Siriraj Hospital. 2011.
- 116. Ergen EK, Akalin H, Yilmaz E, et al. . *Med Mal Infect*. 2009;39:382–387.
- 626 117. Dial S, Delaney JAC, Barkun AN, et al. . JAMA. 2005;294:2989–2995.
- 118. Dial S, Kezouh A, Dascal A, et al. C Can Med Assoc J. 2008;179:767–772.
- Marwick CA, Yu N, Lockhart MC, et al. J Antimicrob Chemother.
 2013;68:2927–2933.
- Suissa D, Delaney JAC, Dial S, et al. . *Br J Clin Pharmacol*. 2012;74:370–
 375.
- 632 121. Wilcox MH, Mooney L, Bendall R, et al. J Antimicrob Chemother.
 633 2008;62:388–396.
- Baxter R, Ray GT, Fireman BH. . Infect Control Hosp Epidemiol.
 2008;29:44–50.
- Haddad FG, Zaidan J, Polavarapu A, et al. . *Z Gastroenterol*. 2019;57:1183–
 1195.
- Kuntz JL, Chrischilles EA, Pendergast JF, et al. . *BMC Infect Dis*;11 . Epub
 ahead of print July 2011. DOI: 10.1186/1471-2334-11-194.
- 640 125. Kutty PK, Woods CW, Sena AC, et al. . *Emerg Infect Dis.* 2010;16:197–204.
- 126. Kwon SS, Gim JL, Kim MS, et al. . *Anaerobe*. 2017;48:42–46.
- 127. Naggie S, Miller BA, Zuzak KB, et al. . *Am J Med*;124 . Epub ahead of print
 March 2011. DOI: 10.1016/j.amjmed.2010.10.013.
- 128. Tabak YP, Johannes RS, Sun X, et al. . *Infect Control Hosp Epidemiol*.
 2015;36:695–701.
- 129. Tartof SY, Rieg GK, Wei R, et al. . *Infect Control Hosp Epidemiol*.
 2015;36:1409–1416.
- Hensgens MPM, Goorhuis A, Dekkers OM, et al. J Antimicrob Chemother.
 2012;67:742–748.
- 131. Nardino RJ, Vender RJ, Herbert PN. . Am J Gastroenterol. 2000;95:3118-

- 651 **3122**.
- 132. Herzig SJ, Howell MD, Ngo LH, et al. JAMA. 2009;301:2120–2128.
- 133. Pham CQD, Regal RE, Bostwick TR, et al. . *Ann Pharmacother*.
 2006;40:1261–1266.
- 134. Freedberg DE, Lebwohl B, Abrams JA. . *Clin Lab Med*. 2014;34:771–785.
- 135. Singh A, Cresci GA, Kirby DF. . Nutr Clin Pract Off Publ Am Soc Parenter
 Enter Nutr. 2018;33:614–624.
- 458 136. van Prehn J, Reigadas E, Vogelzang EH, et al. . *Clin Microbiol Infect*.
 2021;27:S1–S21.
- 137. Furuya-Kanamori L, Stone JC, Clark J, et al. . *Infect Control Hosp Epidemiol*.
 2015;36:132–141.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Figure 1. CDI prevalence in Northwest Bueltos marges available under a CC-BY-NC-ND 4.0 International license.

Figure 2. CDI associated Risk factors. It is made available under a CC-BY-NC-ND 4.0 International license .

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Figure 4. Flow chart of studies screened anis inadecevaliable and a carb an

Figure 5. Forestplots of risk predictors. It is made available under a CC-BY-NC-ND 4.0 International license .

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Supplementary figure 1. Sanitary Region I litos maden available, under a 100aBY-NC-ND 4.0 International license.

Supplementary Figure 1. Sanitary Region III of Buenos Aires, Argentina.

Sanitary region from the northwest of Buenos Aires province (Argentina) comprised of the municipalities of: Chacabuco, F. Ameghino, General Arenales, General Pinto, General Viamonte, Junín, Leandro N. Alem and Lincoln. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Supplementary figure 2. Diagnostic algorithmade wallable of deligic lice by events and a supplementary figure 3.

Supplementary Figure 2. Diagnostic algorithm to determine *C. difficile* presence in stool samples.

A cohort of 249 patients with gastrointestinal symptoms and diarrhea was evaluated. The presence of *C. difficile* within stool samples was ascertained by an algorithm that includes 3 tests (EIA, PCR, and toxigenic culture), accompanied by an exhaustive analysis of the patients' medical records. This algorithm was designed based on Crobach et al. recommendations ¹.

GDH, glutamate dehydrogenase from C. difficile.

Supplementary figure 3. Clinical data from Cip maded and be directed a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 3. Clinical data from CDI+ and CDI- patients.

After classifying the patients into CDI+ or CDIpopulations using the diagnostic algorithm, data from clinical records was evaluated. a) Type of hospitalization room b) requirement of ICU, c) diarrhea classification d) presence of shock, e) death, f) precedence of the patients, g) CDI origin in both populations.

ICU= Intensive Care Unit. HO= Hospitalacquired CDI. CO= Community-acquired CDI. CO-HCFA= Community-acquired CDI associated to hospital environments.

a, b, c, d, e) Fisher's exact test; f, g) Chi-square test with Kruskal Wallis test. ns= non-significant

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Table 1. Clinical, demographic and blood parlsmade available under a Corpartized to 1.0 International license.

Clinical-demographical parameters	Blood parameters
Age	Leukocytes (cells/mm ³)
Biological Sex	Neutrophils (cells/mm ³)
Previous hospitalization	Monocytes (cells/mm ³)
Previous consumption of Antibiotics	Lymphocytes (cells/mm ³)
Antibiotics use during hospitalization	Eosinophils (cells/mm ³)
Presence of comorbidities	Basophils (cells/mm ³)
Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm ³)
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Table 2. Countries and studies included in the made availables under a CC-BY-NC-ND 4.0 International license.

Countries	Studies		
Argentina	Lopardo, G. et al, 2015 39		
	OUR study		
Brazil	Lopes Cançado, G. G. et al, 2018 92		
Canada	Lowe, D. O. et al, 2006 93		
	Dai, W. et al. 2020 94		
China	LI, Y. et al. 2010 50		
Gillia	LV, Z. et al, 2014		
	7hou E E et al 2014 98		
	Carvaial C. et al. 2017 99		
Colombia	Salazar C L et al 2017 ¹⁰⁰		
Denmark	Soes, L. M. et al. 2014 ¹⁰¹		
France	Le Monnier, A. et al, 2022 102		
Hungary	Kurti, Z. et al, 2015 ¹⁰³		
Iceland	Vesteinsdottir, I. et al, 2012 ¹⁰⁴		
India	Ingle, M. et al, 2011 ¹⁰⁵		
india	Ingle, M. et al, 2013 ¹⁰⁶		
Japan	Mon, N. et al, 2015 107		
Mexico	Morfin-Otero, R. et al, 2016 100		
Poland			
South Africa	Rajabally N et al 2013 ¹¹¹		
South Korea	Han, S, H, et al. 2014^{112}		
Taliana	Lee, Y. C. et al, 2012 ¹¹³ ; Lin		
laiwan	C. Y. et al, 2022 ¹¹⁴		
Thailand	Thipmontree, W. et al, 2011 ¹¹⁵		
Turkey	Ergen, E. K. et al, 2009 ¹¹⁶		
	Dial, S. et al, 2005 117		
	Dial, S. et al, 2008 118		
United Kingdom	Marwick, C. A. et al, 2013 119		
	Wilcox M H at al 2008 121		
	Baxter R et al 2008 122		
	Haddad, F. G. et al. 2019 123		
	Kuntz, J. L. et al. 2011 ¹²⁴		
United Ciston	Kutty, P. K. et al, 2010 ¹²⁵		
United States	Kwon, S. et al, 2017 126		
	Naggie, S. et al, 2011 ¹²⁷		
	Tabak, P. Y. et al, 2015 ¹²⁸		
	Tartof, S. Y. et al, 2015 ¹²⁹		

Table 3. Summary of risk predictors from the smade available under a CC-BY-NC-ND 4.0 International license .

RISK PREDICTOR	OR
Age	1,19 **
Biological sex	0,89 *
Prior ATB consumption	3,02 ***
Prior PPI consumption	1,29 ns
Prior hospitalization	2,45 ***
Prior CDI	1,76 ns
WBC (10 ⁹ cel/mm ³)	1,35 *
Platelets (10 ⁹ cel/mm ³)	1,54 ns
Comorbidities	
Diabetes mellitus	1,26 ns
Heart disease	1,41 *
Kidney disease	2,23 ***
HIV	1,00 ns

Table 4. Meta-analysis dataset. It is made available under a CC-BY-NC-ND 4.0 International license .

6		CDI+	CDI-	TOTAL
N° of individuals		11596	536467	548467
Sev	Male	44.33%	39.98%	40.06%
Jex	Female	55.67%	60.02%	59.94%
Prior ATP consumption	With	39.95%	8.52%	9.11%
Filor ATB consumption	Without	60.05%	91.48%	90.89%
Prior PDI consumption	With	29.87%	21.76%	22.18%
Frior FFI consumption	Without	70.13%	78.24%	77.82%
Brier beenitelization	With	27.88%	16.80%	17.07%
Filor nospitalization	Without	72.12%	83.20%	82.93%